30 Mar 23
A small company with novel an X ATMP for Graft vs Host Disease (GvHD) (cell therapy for the treatment and prevention of GvHD).
tranScrip worked with the company to:
Orphan Drug designation for prevention of GvHD was achieved Agreement with EMA on phase 2 design and major design elements for phase 3 was reached.
Get in touch to see how our senior cross-functional experts can help you reduce risk, protect value, and move forward with confidence.